NCT00213096已完成2 期
A Randomized, Open-Label Study Comparing the Effect of a Contraceptive Vaginal Ring Delivering Daily Doses of 150 Micrograms Nestorone and 15 Micrograms Ethinyl Estradiol to an Oral Contraceptive Containing 150 Micrograms of Levonorgestrel and 30 Micrograms of Ethinyl Estradiol Per Tablet on Hepatic Factors Including Coagulation Factors
Population Council1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2003年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Comparison of the differences between contraceptive vaginal ring and oral contraceptive treatment groups in change from baseline to end of treatment in serum angiotensinogen and sex-hormone binding globulin.
研究概览
简要总结
The purpose of this 3-month (cycle) study was to evaluate the effects of hormonal contraceptives containing a progestin and an estrogen on liver proteins and coagulation factors that are sensitive to estrogen. In this study, a contraceptive vaginal ring containing Nestorone® (a progestin with no androgenic properties) and ethinyl estradiol was compared to an oral contraceptive containing levonorgestrel (an androgenic progestin) and ethinyl estradiol.
详细描述
The purpose of this 3-month (cycle) study was to evaluate the effects of hormonal contraceptives containing a progestin and an estrogen on liver proteins and coagulation factors that are sensitive to estrogen. In this study, a contraceptive vaginal ring containing Nestorone® (a progestin with no androgenic properties) and ethinyl estradiol was compared to an oral contraceptive containing levonorgestrel (an androgenic progestin) and ethinyl estradiol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 34 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy women, aged 18-34 years, who did not wish to become pregnant for 3 months (or 5 months if first discontinuing oral contraceptives
- •Intact uterus and at least 1 ovary
- •Have regular menstrual cycles (28 ± 7 days) or 2 regular cycles after parturition or abortion
- •Willing to use condoms while having sexual intercourse during the 3 month study (or 5 months if discontinuing oral contraceptives), or
- •Willing to continue use of a specified non-hormonal method of birth control including permanent sterilization, non-hormone-containing IUD, male condoms, or abstinence during the study or to use condoms if discontinuing one of these methods
- •Willing and able to comply with the protocol
- •Willing and able to sign informed consent prior to entry into the study and prior to discontinuing another method of contraception
- •Easy venous access
排除标准
- •Pregnancy
- •Known hypersensitivity to estrogens or progestins
- •Known hypersensitivity to silicone rubber
- •Undiagnosed vaginal discharge or vaginal lesions or abnormalities
- •Smoking status: >15 cigarettes per day
- •Breastfeeding
- •Current or past thrombophlebitis or thromboembolic disorders
- •Family history of venous thrombosis or embolism (1st degree relatives <55 years of age)
- •Known history of Factor V Leiden or positive screening test for APC-resistance
- •Current or past cerebrovascular or coronary artery disease
- •Carcinoma (hormone-dependent tumor; past history of any carcinoma not in remission for >5 years)
- •Medically diagnosed severe depression
- •Headaches with focal neurological symptoms
- •Undiagnosed abnormal genital bleeding
- •History of cholestatic jaundice of pregnancy or jaundice with prior steroid use
- •Benign or malignant liver tumors; active liver disease
- •Diastolic/systolic BP ≥90/140 mmHg after 5 min. rest
- •Known or suspected alcoholism (>2 drinks/day)or drug abuse
- •Positive for hepatitis B & C and/or HIV 1 or 2, abnormal screening CBC, serum chemistry values (including fasting, total cholesterol and triglycerides), abnormal Pap smear, abnormal findings on dipstick urinalysis, or an abnormal electrocardiogram (ECG)
- •Participation in a clinical trial within last 3 months or more than 1 trial in the last year
- •BMI (kg/m2) >28
- •Use of injectable contraceptives in last 6 months (e.g. cyclofem or DMPA)
- •Unwilling to stop oral contraceptives for 2 months prior to study initiation
- •Use of implanted hormonal contraceptives, including Mirena or Implanon, in last 2 years
- •Not living in the catchment area of the clinic*Severe cystoceles or rectoceles
结局指标
主要结局
Comparison of the differences between contraceptive vaginal ring and oral contraceptive treatment groups in change from baseline to end of treatment in serum angiotensinogen and sex-hormone binding globulin.
次要结局
- Comparison of the differences between contraceptive vaginal ring & oral contraceptive treatment groups in change from baseline to end of treatment in serum or plasma concentrations of 15 other hepatic proteins, coagulation factors & coagulation markers.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Birth Control Pill vs Birth Control Patch StudyVenous ThrombosisNCT00554632University of Vermont24
已完成
4 期
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl EstradiolContraceptionNCT00307632Janssen-Cilag Farmaceutica Ltda.580
已完成
3 期
A Study of Efficacy and Safety With the Transdermal Contraceptive System.ContraceptionFemale ContraceptionNCT00236769Johnson & Johnson Pharmaceutical Research & Development, L.L.C.1,751
已完成
1 期
A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral ContraceptivesFollicle DevelopmentOvarian FollicleFollicle CountFollicle SizeOral ContraceptiveNCT01291004Teva Branded Pharmaceutical Products R&D, Inc.206
已完成
3 期
Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal & Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)ContraceptionNCT00511355Organon and Co121